clotrimazole ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
719 23593-75-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clotrimazole
  • lotrimin
  • rimazole
  • locasten
An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.
  • Molecular weight: 344.84
  • Formula: C22H17ClN2
  • CLOGP: 5
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 17.82
  • ALOGS: -5.37
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g V

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.07 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Feb. 3, 1975 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 452.65 13.31 157 11529 14231 50579207
Schizoaffective disorder 236.37 13.31 62 11624 2144 50591294
Drug level increased 124.78 13.31 69 11617 19199 50574239
Electrocardiogram QT prolonged 67.46 13.31 71 11615 51815 50541623
Sinus rhythm 45.36 13.31 13 11673 627 50592811
Vanishing bile duct syndrome 40.97 13.31 12 11674 625 50592813
Eye infection toxoplasmal 40.48 13.31 10 11676 270 50593168
Vulvovaginal candidiasis 39.88 13.31 17 11669 2675 50590763
Oral candidiasis 33.07 13.31 29 11657 16886 50576552
Purpura senile 29.82 13.31 9 11677 520 50592918
Vulvovaginal inflammation 28.68 13.31 9 11677 593 50592845
Tongue blistering 28.45 13.31 11 11675 1347 50592091
Febrile neutropenia 27.50 13.31 66 11620 97601 50495837
Tarsal tunnel syndrome 25.43 13.31 8 11678 531 50592907
Swollen tongue 23.54 13.31 31 11655 28599 50564839
Candida infection 23.37 13.31 28 11658 23495 50569943
Angiodermatitis 22.96 13.31 5 11681 76 50593362
Drug interaction 21.37 13.31 97 11589 199524 50393914
Post viral fatigue syndrome 20.80 13.31 6 11680 296 50593142
Resorption bone increased 20.51 13.31 8 11678 1003 50592435
Swelling of eyelid 18.81 13.31 9 11677 1851 50591587
Aplastic anaemia 18.77 13.31 15 11671 7688 50585750
Vestibular disorder 18.75 13.31 8 11678 1261 50592177
Reperfusion arrhythmia 17.59 13.31 5 11681 234 50593204
Therapeutic product effect decreased 17.26 13.31 5 11681 136045 50457393
Chronic sinusitis 17.22 13.31 13 11673 6132 50587306
Rheumatoid arthritis 17.18 13.31 13 11673 202537 50390901
Glossodynia 17.16 13.31 3 11683 115566 50477872
Stevens-Johnson syndrome 17.03 13.31 23 11663 21729 50571709
Conjunctivitis 15.68 13.31 19 11667 16126 50577312
Toxicity to various agents 15.19 13.31 16 11670 212483 50380955
Vulvovaginal discomfort 15.13 13.31 8 11678 2033 50591405
Congenital absence of bile ducts 15.12 13.31 3 11683 28 50593410
Dysuria 14.96 13.31 25 11661 28479 50564959
Neuropathy peripheral 14.31 13.31 52 11634 96705 50496733
Oedema mouth 14.26 13.31 8 11678 2282 50591156
Treatment failure 14.22 13.31 7 11679 137630 50455808
Swelling face 14.21 13.31 35 11651 52560 50540878
Stoma site haemorrhage 14.13 13.31 6 11680 935 50592503
Post transplant distal limb syndrome 14.05 13.31 4 11682 188 50593250
Foetal death 13.97 13.31 13 11673 8167 50585271
Urinary tract infection 13.95 13.31 94 11592 223926 50369512
Mouth ulceration 13.94 13.31 24 11662 28000 50565438
Vertigo positional 13.58 13.31 8 11678 2503 50590935
Exfoliative rash 13.52 13.31 8 11678 2522 50590916

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cellulitis 22.87 15.93 36 5792 45804 29522895
Skin infection 20.72 15.93 14 5814 6513 29562186
Lip haemorrhage 20.20 15.93 7 5821 738 29567961
Accident 19.62 15.93 11 5817 3677 29565022
Rash pruritic 19.44 15.93 23 5805 22340 29546359
Aplastic anaemia 18.95 15.93 14 5814 7496 29561203
Temperature regulation disorder 17.82 15.93 6 5822 580 29568119
Microtia 17.56 15.93 5 5823 277 29568422
Congenital umbilical hernia 17.37 15.93 5 5823 288 29568411
Lymphopenia 17.17 15.93 17 5811 13516 29555183
Leukopenia 16.83 15.93 35 5793 55168 29513531

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vulvovaginal candidiasis 44.62 13.53 17 14096 2113 64482506
Aplastic anaemia 39.42 13.53 29 14084 13891 64470728
Eye infection toxoplasmal 35.53 13.53 10 14103 477 64484142
Vanishing bile duct syndrome 33.40 13.53 12 14101 1265 64483354
Oral candidiasis 32.00 13.53 32 14081 23180 64461439
Rash pruritic 31.68 13.53 50 14063 57354 64427265
Tongue blistering 29.55 13.53 11 14102 1282 64483337
Febrile neutropenia 26.70 13.53 96 14017 187561 64297058
Drug ineffective 26.41 13.53 95 14018 840152 63644467
Tarsal tunnel syndrome 26.37 13.53 8 14105 497 64484122
Purpura senile 26.28 13.53 8 14105 503 64484116
Toxicity to various agents 25.71 13.53 25 14088 363488 64121131
Swollen tongue 24.40 13.53 34 14079 34920 64449699
Angiodermatitis 23.36 13.53 5 14108 74 64484545
Candida infection 22.59 13.53 31 14082 31388 64453231
Stevens-Johnson syndrome 21.97 13.53 32 14081 34217 64450402
Post viral fatigue syndrome 21.08 13.53 6 14107 298 64484321
Swelling of eyelid 20.86 13.53 10 14103 2182 64482437
Gingival swelling 20.52 13.53 12 14101 3908 64480711
Overdose 20.23 13.53 5 14108 159561 64325058
Resorption bone increased 19.81 13.53 8 14105 1160 64483459
Vulvovaginal inflammation 18.38 13.53 6 14107 474 64484145
Urinary tract infection 18.06 13.53 99 14014 231497 64253122
Wound complication 17.85 13.53 11 14102 3937 64480682
Oral mucosal blistering 17.34 13.53 12 14101 5225 64479394
Reperfusion arrhythmia 16.87 13.53 5 14108 287 64484332
Lip haemorrhage 16.60 13.53 7 14106 1132 64483487
Plicated tongue 16.59 13.53 4 14109 103 64484516
Pruritus 15.98 13.53 120 13993 312280 64172339
Therapeutic product effect decreased 15.87 13.53 3 14110 115348 64369271
Cellulitis 15.12 13.53 50 14063 93607 64391012
Genital rash 14.90 13.53 6 14107 863 64483756
Swelling face 14.82 13.53 37 14076 59129 64425490
Kidney transplant rejection 14.77 13.53 14 14099 9497 64475122
Vestibular disorder 14.66 13.53 8 14105 2285 64482334
Vulvovaginal discomfort 14.51 13.53 7 14106 1548 64483071
Accident 14.47 13.53 12 14101 6834 64477785
Rash 14.20 13.53 158 13955 458391 64026228
Post transplant distal limb syndrome 13.94 13.53 5 14108 525 64484094
Nephrogenic systemic fibrosis 13.88 13.53 11 14102 5881 64478738
Vulvovaginal pain 13.83 13.53 7 14106 1715 64482904
Foetal death 13.81 13.53 11 14102 5919 64478700
Blister 13.77 13.53 44 14069 80923 64403696
Faeces discoloured 13.63 13.53 22 14091 25707 64458912
Mouth ulceration 13.58 13.53 25 14088 32419 64452200

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A01AB18 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Antiinfectives and antiseptics for local oral treatment
ATC D01AC01 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Imidazole and triazole derivatives
ATC G01AF02 GENITO URINARY SYSTEM AND SEX HORMONES
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
Imidazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D058888 14-alpha Demethylase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000891 Anti-Infective Agents, Local
MeSH PA D000935 Antifungal Agents
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D065088 Steroid Synthesis Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Tinea pedis indication 6020002 DOID:12403
Candidiasis of skin indication 49883006
Pityriasis versicolor indication 56454009 DOID:9060
Candidal vulvovaginitis indication 72605008 DOID:2272
Candidiasis of mouth indication 79740000 DOID:14262
Tinea corporis indication 84849002
Diaper rash indication 91487003
Tinea cruris indication 399029005
Prevention of Oropharyngeal Candidiasis indication
Oropharyngeal Candidiasis indication
Paronychia off-label use 71906005 DOID:13117
Telangiectasia disorder contraindication 247479008
Abdominal pain - cause unknown contraindication 314212008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Fungal infections caused by Microsporum canis Indication
Cats Fungal infections caused by Trichophyton mentagrophytes Indication
Cats Otitis externa caused by yeast, Malassezia pachydermatis Indication
Dogs Fungal infections caused by Microsporum canis Indication
Dogs Fungal infections caused by Trichophyton mentagrophytes Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Veltrim 1% Dermatologic Cream Elanco US Inc. 1
Otomax Intervet Inc. 3
Mometamax Otic Suspension Intervet Inc. 3
Tri-Otic Ointment Med-Pharmex Inc. 3
Vetro-Max Fougera Pharmaceuticals Inc. 3
GBC Ointment Cronus Pharma Specialities India Private Limited 3
Mometavet Med-Pharmex Inc. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.4 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR Ki 5.19 DRUG MATRIX
Prostaglandin G/H synthase 2 Enzyme IC50 4.38 DRUG MATRIX
Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor ANTAGONIST IC50 6.16 IUPHAR
Mu-type opioid receptor GPCR Ki 6.14 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.35 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.39 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 5.15 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 5.35 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.52 CHEMBL
Cytochrome P450 3A4 Enzyme IC50 7.70 WOMBAT-PK
Multidrug resistance protein 1 Transporter IC50 5.17 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 5.51 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.10 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.00 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 5.50 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.13 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.12 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.24 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.43 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.05 DRUG MATRIX
Histamine H1 receptor GPCR Ki 5.47 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.29 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 5.78 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.29 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 5.68 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 5.79 DRUG MATRIX
Glucocorticoid receptor Nuclear hormone receptor Ki 5.83 DRUG MATRIX
Beta-3 adrenergic receptor GPCR Ki 5.27 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.35 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 5.11 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.57 DRUG MATRIX
Intermediate conductance calcium-activated potassium channel protein 4 Ion channel IC50 7.15 CHEMBL
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor WOMBAT-PK
D(4) dopamine receptor GPCR Ki 5.16 DRUG MATRIX
Carbonic anhydrase 2 Enzyme IC50 4.52 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.13 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.60 DRUG MATRIX
Delta-type opioid receptor GPCR Ki 5.76 DRUG MATRIX
Acetylcholinesterase Enzyme IC50 4.71 DRUG MATRIX
Cytochrome P450 2C9 Enzyme IC50 7.80 DRUG MATRIX
Platelet-activating factor receptor GPCR Ki 4.65 DRUG MATRIX
Aromatase Enzyme IC50 8.74 CHEMBL
Cysteinyl leukotriene receptor 1 GPCR Ki 4.78 CHEMBL
Epidermal growth factor receptor Kinase IC50 4.16 DRUG MATRIX
Vasopressin V2 receptor GPCR IC50 5.60 CHEMBL
Substance-P receptor GPCR Ki 5.06 DRUG MATRIX
Steroid 17-alpha-hydroxylase/17,20 lyase Enzyme IC50 7.09 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 3 Ion channel IC50 5.22 CHEMBL
Cytochrome P450 2C19 Enzyme IC50 7.80 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 4.50 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 4.18 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 7.85 DRUG MATRIX
Bile acid receptor Nuclear hormone receptor IC50 5.49 CHEMBL
Lanosterol 14-alpha demethylase Enzyme IC50 6.89 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.92 CHEMBL
Substance-K receptor GPCR Ki 5.47 DRUG MATRIX
C-C chemokine receptor type 4 GPCR IC50 5.80 CHEMBL
C-X-C chemokine receptor type 1 GPCR IC50 5.70 CHEMBL
Transitional endoplasmic reticulum ATPase Enzyme IC50 5.85 CHEMBL
Malate dehydrogenase cytoplasmic Enzyme IC50 4.46 CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Enzyme IC50 6.10 CHEMBL
Lanosterol 14-alpha demethylase Enzyme INHIBITOR CHEMBL CHEMBL
Beta-lactamase Enzyme IC50 4.70 CHEMBL
Androgen receptor Transcription factor Ki 5.11 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 4.91 DRUG MATRIX
Cysteinyl leukotriene receptor 1 GPCR Ki 4.78 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.94 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 4.58 CHEMBL
Lanosterol 14-alpha demethylase Enzyme Kd 6.70 CHEMBL
14-alpha sterol demethylase Cyp51A Enzyme Kd 5.32 CHEMBL
14-alpha sterol demethylase Enzyme Kd 6.99 CHEMBL
Indoleamine 2,3-dioxygenase 2 Enzyme IC50 5.23 CHEMBL
Mycocyclosin synthase Enzyme Kd 7.14 CHEMBL
Putative cytochrome P450 130 Enzyme Kd 4.88 CHEMBL
Alpha-chymotrypsin Enzyme IC50 4.07 CHEMBL
Indoleamine 2,3-dioxygenase 1 Enzyme IC50 4.29 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 4.75 CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Enzyme Ki 4.46 CHEMBL

External reference:

IDSource
4018265 VUID
N0000146595 NUI
D00282 KEGG_DRUG
202859 RXNORM
4018265 VANDF
C0009074 UMLSCUI
CHEBI:3764 CHEBI
CL6 PDB_CHEM_ID
CHEMBL104 ChEMBL_ID
DB00257 DRUGBANK_ID
D003022 MESH_DESCRIPTOR_UI
2812 PUBCHEM_CID
2330 IUPHAR_LIGAND_ID
2912 INN_ID
G07GZ97H65 UNII
1284 MMSL
4482 MMSL
d01236 MMSL
002916 NDDF
387325003 SNOMEDCT_US
5797005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-4146 LOZENGE 10 mg ORAL ANDA 14 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-8146 LOZENGE 10 mg ORAL ANDA 14 sections
Lotrisone HUMAN PRESCRIPTION DRUG LABEL 2 0085-0924 CREAM 10 mg TOPICAL NDA 26 sections
Good Sense Athletes Footantifungal HUMAN OTC DRUG LABEL 1 0113-0857 CREAM 1 g TOPICAL OTC monograph final 13 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0168-0133 CREAM 10 mg TOPICAL ANDA 20 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0168-0258 CREAM 10 mg TOPICAL ANDA 27 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0168-0370 LOTION 10 mg TOPICAL ANDA 20 sections
Fungicure Liquid Gel HUMAN OTC DRUG LABEL 1 0295-1363 LIQUID 10 mg TOPICAL OTC monograph final 9 sections
Fungicure Manicure Pedicure Anti Fungal HUMAN OTC DRUG LABEL 1 0295-6307 LIQUID 1 mg TOPICAL OTC monograph final 10 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-0220 CREAM 10 mg VAGINAL ANDA 16 sections
WALGREENS CLOTRIMAZOLE HUMAN OTC DRUG LABEL 1 0363-1299 CREAM 1 g TOPICAL OTC monograph final 11 sections
athletes foot HUMAN OTC DRUG LABEL 1 0363-1857 CREAM 1 g TOPICAL OTC monograph final 13 sections
Walgreens Clotrimazole 3 HUMAN OTC DRUG LABEL 1 0363-2062 CREAM 2 g VAGINAL NDA 16 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-2105 CREAM 10 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Ringworm HUMAN OTC DRUG LABEL 1 0363-2107 CREAM 10 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Walgreens Jock Itch HUMAN OTC DRUG LABEL 1 0363-2109 CREAM 10 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-3492 LIQUID 1 mg TOPICAL OTC monograph final 8 sections
Walgreens Clotrimazole Antifungal HUMAN OTC DRUG LABEL 1 0363-7412 CREAM 1 g TOPICAL OTC monograph final 11 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0472-0220 CREAM 10 mg VAGINAL ANDA 16 sections
ClotrimazoleAntifungal HUMAN OTC DRUG LABEL 1 0472-0350 CREAM 10 mg TOPICAL OTC monograph final 13 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0472-0379 CREAM 10 mg TOPICAL ANDA 24 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0536-1181 SOLUTION 1 g TOPICAL OTC monograph final 13 sections
Rugby Clotrimazole Antifungal Cream HUMAN OTC DRUG LABEL 1 0536-1265 CREAM 1 g TOPICAL OTC monograph final 12 sections
RUGBY ANTIFUNGAL CLOTRIMAZOLE HUMAN OTC DRUG LABEL 1 0536-1272 CREAM 0.01 g TOPICAL OTC monograph final 14 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0574-0107 LOZENGE 10 mg ORAL ANDA 18 sections
Major Clotrimazole HUMAN OTC DRUG LABEL 1 0904-7822 CREAM 10 mg TOPICAL OTC monograph final 11 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 10135-671 SOLUTION 1 g TOPICAL OTC monograph final 13 sections
Lotrimin HUMAN OTC DRUG LABEL 1 11523-0963 CREAM 10 mg TOPICAL OTC monograph final 14 sections
LotriminAntifungal HUMAN OTC DRUG LABEL 1 11523-1125 CREAM 10 mg TOPICAL OTC monograph final 14 sections
Lotrimin HUMAN OTC DRUG LABEL 1 11523-6549 CREAM 10 mg TOPICAL OTC monograph final 14 sections